Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Crossbow Therapeutics | 2025 | Series Unknown | $30.3M | Cambridge |
| Volastra Therapeutics | 2025 | Series A | $30.1M | New York |
| Dualitas Therapeutics | 2025 | Series A | $65.0M | San Francisco |
| Remedium Bio | 2025 | Corporate Round | Undisclosed | Needham |
| HAYA Therapeutics | 2025 | Grant | Undisclosed | Lausanne |
| Incyclix Bio | 2025 | Series B | $11.2M | Durham |
| LTZ Therapeutics | 2025 | Corporate Round | Undisclosed | San Francisco |
| Auron Therapeutics | 2025 | Series Unknown | Undisclosed | Newton |
| Laverock Therapeutics | 2025 | Seed | Undisclosed | Stevenage |
| Signify Bio | 2025 | Series Unknown | $15.0M | Dallas |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Crossbow Therapeutics | Series Unknown | $30.3M | Cambridge, United States |
| 52 | Volastra Therapeutics | Series A | $30.1M | New York, United States |
| 53 | Dualitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 54 | Remedium Bio | Corporate Round | Undisclosed | Needham, United States |
| 55 | HAYA Therapeutics | Grant | Undisclosed | Lausanne, Switzerland |
| 56 | Incyclix Bio | Series B | $11.2M | Durham, United States |
| 57 | LTZ Therapeutics | Corporate Round | Undisclosed | San Francisco, United States |
| 58 | Auron Therapeutics | Series Unknown | Undisclosed | Newton, United States |
| 59 | Laverock Therapeutics | Seed | Undisclosed | Stevenage, United Kingdom |
| 60 | Signify Bio | Series Unknown | $15.0M | Dallas, United States |
Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Signify Bio is a biotechnology company harnessing the human body for the production of in situ protein therapeutics.
Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.
Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Persist AI is a biotechnology company that builds long-acting microsphere formulations.
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
Maxion Therapeutics helps in learning transformative therapies.
Trans Solutions Research and Resource Center empowers transgender and gender communities.
TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Revisto is a pioneer AI-powered technology that simplifies the medical, legal, and regulatory review process for life sciences marketing.
Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.
Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes.
Eli Lilly has invested in 110 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Eli Lilly's top investment sectors include Biotechnology, Medical, Therapeutics, Health Care, Pharmaceutical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Orbis Medicines received $93.5M in a Series A round. Eli Lilly's total known invested capital is $4.1B.
Eli Lilly's average investment size is $49.3M across its portfolio of 110 companies.
Recent Eli Lilly portfolio additions include Crossbow Therapeutics, Volastra Therapeutics, Dualitas Therapeutics, Remedium Bio, HAYA Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors